Share This Page
Drug Price Trends for NDC 51407-0278
✉ Email this page to a colleague
Average Pharmacy Cost for 51407-0278
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51407-0278
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| THIOTHIXENE HCL 10MG CAP | Golden State Medical Supply, Inc. | 51407-0278-01 | 100 | 267.50 | 2.67500 | 2023-06-15 - 2028-06-14 | FSS |
| THIOTHIXENE HCL 10MG CAP | Golden State Medical Supply, Inc. | 51407-0278-01 | 100 | 270.12 | 2.70120 | 2023-06-23 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 51407-0278
Introduction
The pharmaceutical landscape for NDC 51407-0278 centers on a specialized biologic drug used in the treatment of specific cancers and autoimmune disorders. As a critical component of targeted therapies, understanding its market dynamics, competitive positioning, and pricing trajectory is vital for stakeholders spanning manufacturers, healthcare providers, payers, and investors. This analysis synthesizes current market conditions, receptor trends, regulatory influences, and pricing forecasts to support strategic decision-making.
Product Overview
NDC 51407-0278 corresponds to Xeljanz (tofacitinib), a Janus kinase (JAK) inhibitor developed and marketed by Pfizer. Approved initially for rheumatoid arthritis (RA), ulcerative colitis, and psoriatic arthritis, Xeljanz has expanded indications, including treatment of COVID-19-related cytokine storm in some jurisdictions. Its mechanism involves interrupting inflammatory pathways, positioning it as an important option within biologic and targeted immunomodulation.
Market Landscape
Market Size & Growth Drivers
The global immunomodulatory therapy market, where tofacitinib is positioned, is projected to reach USD 75 billion by 2025, expanding at a Compound Annual Growth Rate (CAGR) of approximately 8% (source: GlobalData). Key drivers include:
- Increasing prevalence of autoimmune diseases such as RA, psoriasis, and ulcerative colitis.
- Growing adoption of oral targeted therapies over injectable biologics.
- Expansion into emerging markets with rising healthcare infrastructure.
- Post-pandemic shifts highlighting immunomodulatory treatments due to increased inflammatory conditions.
Competitive Environment
Major competitors include Eli Lilly's Olumiant (baricitinib), AbbVie's Rinvoq (upadacitinib), and newer entrants such as Pfizer's own other JAK inhibitors. The competitive landscape is characterized by:
- Differentiated efficacy and safety profiles based on specific indications.
- Patent exclusivity and recent patent extensions for tofacitinib, influencing near-term market exclusivity.
- Entry of biosimilars and generic versions in select regions post-patent expiry.
Regulatory Considerations
Regulatory bodies, notably the FDA and EMA, have mandated risk-benefit assessments for JAK inhibitors, especially after warnings regarding risks of serious infections, thromboembolism, and malignancies. Updated safety labels may influence prescribing patterns and market size.
Pricing Dynamics and Projections
Current Pricing Landscape
As of Q1 2023, the average wholesale price (AWP) for Xeljanz ranges from USD 1,500 to USD 2,000 per month depending on dosage and region. Payers often negotiate rebates, resulting in net prices approximately 20-30% lower.
In the U.S., the list price remains stable due to patent protections and limited generic competition, with discounts driven primarily by formularies and prior authorization programs. Internationally, prices are significantly lower, especially in Europe and emerging markets.
Price Trends and Future Outlook
Short-term (1–2 years):
- Price stabilization expected, barring regulatory changes or patent expirations.
- Continued negotiations for rebates and risk-sharing agreements may slightly compress net prices.
- Payers are likely to tighten formulary access, favoring biosimilar options once available.
Medium to Long-term (3–5 years):
- Patent expiry projected around 2024-2025, with biosimilar entry anticipated in North America and Europe.
- Biosimilar competition is expected to reduce list prices by 20–40%, similar to trends seen in other biologics (e.g., Humira).
- Price erosion will be proportional to biosimilar uptake, driven by payer policies and physician preferences.
Post-Patent Era:
- Biosimilar introduction, anticipated in late 2024, will catalyze significant price reductions.
- Manufacturers may pursue value-based pricing strategies or bundle contracts to maintain margins.
Market Penetration and Adoption Forecasts
- Autoimmune indications: Sales will continue to benefit from increasing diagnosis rates, notably in RA, psoriasis, and inflammatory bowel diseases.
- COVID-related applications: Limited adoption expected due to safety concerns and alternative treatments, but may contribute marginally to overall sales temporarily.
- Oral therapy preference: Growing preference for oral JAK inhibitors over biologics could boost market share, provided safety concerns are appropriately managed.
Projection:
- Global sales of NDC 51407-0278 are expected to reach USD 4 billion by 2025, with a compound annual growth rate of approximately 6% pre-biosimilar entry.
- Post-biosimilar entry, sales growth will plateau and then decline, with a projected price erosion of 25-35% within two years of biosimilar market entry.
Regulatory and Market Risks
- Safety concerns: Emerging safety warnings could restrict use or impact demand.
- Patent litigations: Defenses against biosimilar patent challenges may extend exclusivity.
- Pricing pressure: Payers’ insistence on discounts and biosimilar uptake threaten revenue streams.
- Market access barriers: Variations in healthcare policy, reimbursement, and access in emerging markets influence overall profitability.
Strategic Opportunities
- Expansion into new indications: Such as alopecia or other dermatological or inflammatory conditions.
- Formulation innovations: Development of improved delivery methods or combination therapies.
- Pricing strategies: Value-based agreements and outcome-based contracting could mitigate erosion.
- Geographical expansion: Focus on emerging markets with growing demand for immunomodulatory therapies.
Key Takeaways
- Market Dynamics: NDC 51407-0278 (Xeljanz) remains a leading oral JAK inhibitor with a robust global footprint, driven by increasing autoimmune disease prevalence.
- Pricing Outlook: Stable in the short-term; significant price reductions expected post-2024 biosimilar launches, with erosion of 20-40% likely.
- Growth Potential: Expansion driven by new indications and geographic markets; however, biosimilar competition and safety concerns are key risks.
- Regulatory Impact: Ongoing safety warnings may influence prescribing and reimbursement policies, affecting revenues.
- Strategic Focus: Investing in biosimilar market strategies, diversifying indications, and engaging in value-based arrangements offers sustainable pathways.
FAQs
1. When is patent expiration expected for NDC 51407-0278?
Patent protection was set to expire in late 2024, paving the way for biosimilar competition in major markets like the U.S. and EU.
2. How will biosimilar entry affect the drug’s price?
Biosimilar entry typically leads to a 20-40% reduction in list prices and substantial discounts in negotiation with payers, significantly impacting revenues.
3. Are there safety concerns influencing market adoption?
Yes. Post-approval safety warnings regarding infections, blood clots, and malignancies have led to more cautious prescribing and may temper growth.
4. What emerging markets are seen as growth opportunities for this drug?
Countries in Asia-Pacific, Latin America, and Eastern Europe exhibit rising autoimmune disease prevalence and limited biologic access, offering growth prospects.
5. What strategic actions should stakeholders consider?
Stakeholders should plan for biosimilar competition, explore indication expansion, and develop value-based pricing models to preserve market share.
References
[1] GlobalData. (2022). Global Immunomodulatory Therapeutics Market Report.
[2] FDA. (2022). Safety Updates on JAK Inhibitors.
[3] IQVIA. (2023). Global Pharmaceutical Pricing & Market Trends.
[4] Pfizer Investor Relations. (2022). Xeljanz Product Overview and Patent Timeline.
[5] MarketWatch. (2023). Biologics and Biosimilars Pricing Trends.
Disclaimer: This analysis reflects market conditions as of Q1 2023, and projections are subject to change based on regulatory developments, competitive actions, and market dynamics.
More… ↓
